Screener
Regenxbio RGNX Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Regenxbio in its filing.
Tagged under the XBRL concept us-gaap:CommonStockValue.
The source filing: Regenxbio’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336725
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Total liabilities | 314,853 | 350,299 |
| Stockholders’ equity | ||
| Preferred stock; $0.0001 par value; 10,000 shares authorized, no shares issued and outstanding at June 30, 2026 and December 31, 2025 | — | — |
| Common stock; $0.0001 par value; 100,000 shares authorized at June 30, 2026 and December 31, 2025; 54,164 and 50,892 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | 5 | 5 |
| Additional paid-in capital | 1,266,004 | 1,229,442 |
| Accumulated other comprehensive loss | (875) | (687) |
| Accumulated deficit | (1,193,369) | (1,126,027) |
| Total stockholders’ equity | 71,765 | 102,733 |
Item 1. Financial Statements.
FAQ
- What is Regenxbio's common stock?
- Regenxbio (RGNX) reported common stock of $5K in Q2 2026.
- How has Regenxbio's common stock changed year-over-year?
- Regenxbio's common stock decreased by 0.0% year-over-year, from $5K to $5K.
- What is the long-term trend for Regenxbio's common stock?
- Over 5 years (2020 to 2025), Regenxbio's common stock has grown at a 4.6% compound annual growth rate (CAGR), from $4K to $5K.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Regenxbio's common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude